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Abstract
Active smokers and those exposed to secondhand smoke are at increased risk of bacterial
infection. Tobacco smoke exposure increases susceptibility to respiratory tract infections, including
tuberculosis, pneumonia and Legionnaires disease; bacterial vaginosis and sexually transmitted
diseases, such as chlamydia and gonorrhoea; Helicobacter pylori infection; periodontitis; meningitis;
otitis media; and post-surgical and nosocomial infections. Tobacco smoke compromises the anti-
bacterial function of leukocytes, including neutrophils, monocytes, T cells and B cells, providing a
mechanistic explanation for increased infection risk. Further epidemiological, clinical and
mechanistic research into this important area is warranted.
Review
It is well established that smokers are more susceptible
than non-smokers to a plethora of chronic diseases and
conditions that include stroke, vascular diseases, chronic
obstructive pulmonary disease, multiple cancers, perio-
dontal diseases, hypertension, impotence and osteoporo-
sis. However, smokers are also significantly more
susceptible to multiple bacterial infections than are non-
smokers. Such infections can be life-threatening and both
active smokers as well as those exposed to secondhand
smoke toxins are at increased risk. This important rela-
tionship between smoking and ill-health may not be uni-
versally appreciated. Therefore, we set out to review and
summarize the evidence associating tobacco smoke expo-
sure with bacterial infections and to introduce interac-
tions between tobacco smoke, bacteria, and the immune
system that may help explain the increased susceptibility
to infectious disease in smokers.
Bacterial infections associated with tobacco 
smoking
Nasopharyngeal and respiratory tract infections
Adult smokers are at increased risk of respiratory infection
by several bacterial pathogens, including Streptococcus
pneumonia, Neisseria meningitidis, Haemophilus influenzae
and  Legionella pneumophila [1-5]. Brook and Gober
reported that the nasopharyngeal microflora of smokers
contains fewer normal bacteria (such as α-hemolytic and
nonhemolytic streptococci, and Prevotella and Peptostrepto-
coccus  species) that can interfere with colonization by
selected pathogens (S. pneumoniae,  H. influenzae (non-
type b), Moraxella catarrhalis, and Streptococcus pyogenes)
and that the nasopharyngeal microflora also contains
more potential pathogens compared with those of non-
smokers[6]. Such increased carriage of potentially patho-
genic species of bacteria in both adults and children was
hypothesized [6] to possibly be due to enhanced bacterial
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binding to the epithelial cells of smokers [7] and the low
number of α-hemolytic streptococci with inhibitory activ-
ity against S. pyogenes in the oral cavities of smokers [6,8].
More recently, the same group followed a small number
of quitters (n = 20) for a period of up to 15 months post-
tobacco cessation, and concluded that the high number of
pathogens (S. pneumoniae, H. influenzae, M. catarrhalis,
and S. pyogenes) and low number of interfering organisms
found in the nasopharynx of smokers reverted to normal
levels after stopping smoking [9].
When comparing patients with stable chronic obstructive
pulmonary disease (COPD) with healthy controls (nor-
mal spirometry and chest radiography) Zalacain et al
found current smoking to be associated (OR 3.17, 95% CI
2.50–8.00) with pulmonary infection with pathogenic
bacteria – H. influenzae, Streptococcus viridans, S. pneumo-
niae and M. catarrhalis being the most frequently cultured
species [10]. In patients with chronic obstructive pulmo-
nary disease (COPD), bacterial exacerbations are also
more prevalent among current smokers (OR 3.77, 95% CI
1.17–12.12) [11,12].
Several studies indicate that exposure to passive smoking
also increases the incidence of sneezing, sore throat,
cough, and frequent cough [13,14]. The incidence of
group A streptococcus sore throat has been reported to be
higher among children living in homes that include a
tobacco smoker [15]. Thus, there is a consistent body of
literature showing a significant association between
tobacco smoke exposure and respiratory tract infections.
More specific pulmonary diseases are now considered.
Cystic Fibrosis
Cystic fibrosis is a life-shortening autosomal recessive dis-
ease affecting the pulmonary, gastrointestinal and geni-
tourinary systems. Lung colonization with a succession of
pathogens, such as Staphylococcus aureus and H. influenzae
is likely to occur in affected individuals. Ultimately, per-
sistent colonization by the opportunistic pathogen Pseu-
domonas aeruginosa contributes to significant morbidity
and mortality in cystic fibrosis [16]. Epidemiological stud-
ies have shown that secondhand smoke exposure is asso-
ciated with poor prognosis in cystic fibrosis patients [17]
and that a dose-dependent relationship exists between
number of cigarettes smoked and severity of disease
amongst young patients [18]. In keeping with these data,
mice infected with P. aeruginosa and exposed to tobacco
smoke exhibit delayed clearance of infection and
increased morbidity compared to control mice which
were infected but not exposed to smoke [19].
Pneumonia, Legionnaires' disease and bronchitis
Several studies have shown smoking to be significantly
associated with the development of bronchitis and bacte-
rial pneumonia [20]. There are dose-response relations
between the current number of cigarettes smoked per day;
pack-years of smoking; and time since quitting and inva-
sive pneumococcal disease, with approximately 50% of
those with invasive pneumococcal disease being cigarette
smokers [2]. Recently, several authors have discussed the
possibility of recommending the routine extension of
pneumococcal vaccine coverage to current smokers
[21,22]. There is also strong evidence that smoking is an
independent risk factor for Legionnaires disease, an atyp-
ical pneumonia that usually develops 2 to 14 days after
exposure to Legionella pneumophila [5,23]. Complications
of Legionnaires' disease can be severe and include respira-
tory failure, septic shock, and acute kidney failure. Indeed,
mortality rates as high as 8.2–13.5% have been reported
in infected individuals among the general populations of
several European countries [24,25]. Studies indicate a
dose dependent relationship between frequency of
Legionnaires disease and passive smoking in children [26]
as well as in adult smokers [27].
Tuberculosis
More than 30% of world's population may be infected
with the bacterial agent of tuberculosis, Mycobacterium
tuberculosis. Tuberculosis represents the leading cause of
death from infectious disease worldwide and the leading
cause of death among HIV-positive individuals [28].
Smoking increases susceptibility to bacillary tuberculosis
in a dose-dependent manner [29,30], adversely affects
clinical manifestations [31], and accounts for 12% of all
tuberculosis deaths [28]. The disease progresses more rap-
idly in smokers than in non-smokers, while smoking is
also associated with increased relapse and mortality [32].
Quitting smoking and prevention of exposure to second-
hand smoke are both important measures in the control
of tuberculosis [33]. Indeed, the W.H.O. has estimated
that, in China, heavy smoking (> 20 cigarettes per day)
leads to a doubling of the death rate from tuberculosis
[28].
Bacterial meningitis
Carriage of H. influenzae, pneumococcus, and meningo-
coccus has been shown to be more common in both
active and second-hand smokers than in nonsmokers [34-
38]. Indeed, the relationship may be dose-dependent and,
in a study of military recruits, smoke exposure gave an
attributable risk for meningococcal carriage of 33% [38].
In addition to increased carriage, meningitis cases have a
two-to fourfold higher risk of exposure to cigarette smoke
than controls [34]. Furthermore, second-hand smoke
exposure predisposes to nasopharyngeal colonization
with specific Staphylococcus aureus variants that may have
altered capacity to compete with pneumococci subtypes
[39]. Passive exposure to tobacco smoke has also beenTobacco Induced Diseases 2008, 4:12 http://www.tobaccoinduceddiseases.com/content/4/1/12
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associated with Hemophilus influenzae and pneumococcus
meningitis in Australian children [4].
Vaginosis and sexually transmitted infections
Bacterial vaginosis, although often asymptomatic, can
cause considerable discomfort and is associated with the
development of more serious infections, such as septi-
cemia and increased risk of poor pregnancy outcome [40-
42]. Tobacco smoking has been significantly correlated
with bacterial vaginosis, typically being in the region of
twice as common in smokers as non-smokers, with a
greater prevalence noted in young women [43-45].
Tobacco use has also been independently associated with
a higher prevalence of specific sexually-transmitted bacte-
rial infections – chlamydia and gonorrhoea [46].
Helicobacter pylori infection
There are several factors that may contribute to an
increased susceptibility to gastric and duodenal ulcers in
smokers compared to non-smokers. Smoking decreases
antacid (bicarbonate) secretion from the pancreas, while
stimulating gastric acid secretion [47,48]. Furthermore,
the great majority of gastric and duodenal ulcers are asso-
ciated with H. pylori infection and smokers are more sus-
ceptible than non-smokers to gastrointestinal infection
with this bacterial species [49-51]. Additionally, smoking
has been significantly associated with the failure of anti-
H. pylori therapy [52,53].
Periodontitis
Patients who smoke exhibit not only increased suscepti-
bility to periodontitis but are also more likely than non-
smokers to display severe disease and to be refractory to
treatment [54]. Despite some conflicting data that smok-
ing may not influence the sub-gingival micoflora [55-58],
the balance of recent data strongly suggests that tobacco-
induced susceptibility to periodontitis is associated with
shifts in the microbial composition of complex periodon-
tal plaque communities smokers [51,59-66], as we have
recently reviewed [54]. For example, Zambon et al
showed a higher prevalence of Aggregatibacter actinomyce-
temcomitans, Tannerella forsythia and Porphyromonas gingi-
valis  in smokers [59]. Umeda et al [63] reported an
increased risk for harbouring Treponema denticola in smok-
ers. Haffajee and Socransky [67] showed an increased
prevalence of eight species, including P. gingivalis, in cur-
rent smokers, while Eggert et al [62] have shown a higher
prevalence and proportion of T. forsythia, Campylobacter
rectus, P. gingivalis and Peptostreptococcus micros in plaque
samples from smokers.
Inflammatory bowel diseases
Of all the factors associated with inflammatory bowel dis-
eases, the most solid evidence is for smoking and enteric
bacterial flora – and these two risk factors may well be
related [68]. Smoking increases the risk of Crohn's disease
and worsens its clinical course, but has a protective effect
in ulcerative colitis [68], as we and others have recently
reviewed [69-71]. Furthermore, in ulcerative colitis
patients, ex-smokers are more likely than current smokers
to exhibit increased disease progression, more frequent
hospitalization, and are twice as likely as current smokers
to require colectomy [72]. However, in Crohn's disease
patients, smokers exhibit higher disease recurrence rates,
require more frequent surgical interventions, and have a
greater need for immunosuppressive agents compared to
non-smokers [72].
Otitis media
Otitis media is an infection of the middle ear, commonly
caused by Moraxella catarrhalis, S. pneumoniae and H. influ-
enzae, that is rarely associated with severe complications,
such as hearing loss and meningitis. The posterior
nasopharynx flora of parents who smoke, compared to
the flora of non-smoking parents, contains more potential
pathogens similar to those recovered from otitis media-
prone children [73]. Additionally, children exposed to
secondhand smoke are more susceptible to otitis media
[1]. Indeed, secondhand smoke has been estimated to be
responsible for 0.7 to 1.6 million physician visits for mid-
dle ear infections annually in the USA alone [74].
Post-Surgical and nosocomial infections
As many as 5% of patients undergoing surgery develop
surgical site infections, which leads to significant morbid-
ity and may sometimes be fatal [75]. Smoking is known to
be an important patient-related risk factor for surgical site
infections [75,76]. Smoking also increases the risk of
nosocomial non-wound infections, bacteremia and uri-
nary tract infections with multiple bacterial species and
worsens bacteremic prognosis [77-80].
In utero and neonatal second-hand smoke exposure, 
neonatal infection and sudden infant death syndrome 
(SIDS)
12% of US women smoke during pregnancy [81] and,
conservatively, 50% of US children are exposed to second-
hand smoke [82,83]. Maternal smoking has been associ-
ated with significantly higher rates of neonatal infection
than found in the children of non-smoking mothers
[82,84,85]. Furthermore, the odds ratios for SIDS in sec-
ondhand smoke-exposed neonates have risen considera-
bly since the broad acceptance of "back-to-sleep"
positioning [82]. It has recently been postulated that these
two facts may be related and that SIDS could be caused by
the interactions between components of cigarette smoke
and infectious bacterial loads that would normally be
sub-lethal in neonates that have not been exposed to
tobacco smoke [82,86-88].Tobacco Induced Diseases 2008, 4:12 http://www.tobaccoinduceddiseases.com/content/4/1/12
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Mechanisms of increased susceptibility to 
bacterial infections in smokers
There is a large and productive tobacco research literature
that focuses on epidemiology, behavior, addiction and
quitting. However, despite the wealth of epidemiological
evidence of the profound ill-effects of smoking on human
health, studies that set out to understand the mechanisms
of how cigarette smoke induces disease are limited, as we
have recently commented [89]. It is not the intent of this
review to provide comprehensive data on why tobacco use
leads to increased rates of infectious disease in smokers.
Rather, we will introduce some of the key potential mech-
anisms underlying this increased susceptibility and pro-
vide the reader with links to more exhaustive literature
reviews.
Cigarette smoking can, theoretically, increase the risk of
infection by pathogenic or opportunistic bacteria by three
general mechanisms:
￿ Tobacco-induced physiological and structural changes
in humans.
￿ Tobacco-induced increase in bacterial virulence.
￿ Tobacco-induced dysregulation of immune function.
Such mechanisms are not mutually exclusive and all three
may occur simultaneously. For example, tobacco smoke
exposure may play a direct role in bacterial colonization
of the respiratory tract by hindering mucociliary clearance
of bacteria [19,90]; while inducing bacterial components
that aid in the binding of microbes to respiratory epithe-
lial cells ([7] and our own, unpublished data); and con-
currently decreasing the ability of respiratory phagocytic
cells to detect and destroy pathogenic microbes [91].
Tobacco-induced physiological and structural changes in
humans have focused primarily on the vasculature and
respiratory tract. The vasoactive effects of cigarette smoke
and nicotine appear to vary in different vascular beds. For
example, smoking induces vasoconstriction in peripheral
arteries [92] but vasodilation in cerebral blood vessels
[93]. In periodontal tissues smoking does not seem to
exert an acute vasoactive (constriction or dilation) influ-
ence on the microvasculature [94]. Rather, smoking
results in a suppression of periodontal angiogenesis [95]
in a manner that is rapidly reversible on smoking cessa-
tion [96]. Thus, the negative influence of smoking on
mucociliary function most likely contributes to increased
risk of bacterial infection by reducing the ability of the res-
piratory tract to clear pathogens, while the vasoconstric-
tive or anti-angiogenic influence of tobacco may
contribute to increased susceptibility to bacterial infection
by decreasing the effectiveness of inflammatory responses
to pathogenic bacteria.
Several research groups have examined the interactions
between infectious agents and cigarette smoke compo-
nents. For example, Sayers et al. have demonstrated the
potentiating influence of low levels of nicotine on staphy-
lococcal and enterobacter toxins in studies addressing
why passive exposure to cigarette smoke is a risk factor in
sudden infant death syndrome [86,87]. The same group
has also shown that both nicotine and cotinine exhibit
lethal synergy with toxins produced by several periodon-
tal pathogens (Prevotella, Porphyromonas and Fusobacterium
species) in the chick embryo toxicity model. Wiedeman et
al. have suggested that tobacco smoke exposure may rep-
resent a risk for establishment of a chronic reservoir of C.
pneumoniae  infection within respiratory epithelium
[97,98]. Other groups have shown that exposure to ciga-
rette smoke affects the growth of bacteria which may facil-
itate populational shifts in the microbial communities
that colonize some human tissues. Zonuz et al reported
that the growth of Streptococcus mutans and S. sanguis, two
common oral bacteria, was stimulated by cigarette smoke
[99]. In contrast, Ertel et al. showed that cigarette smoke
inhibited the growth of Gram positive organisms, e.g., S.
pneumoniae and S. aureus, but had little effect on Gram
negative enteric bacteria such as Klebsiella, Enterobacter
and Pseudomonas [100]. Consistent with this observation,
they report that smokers have a propensity to develop
heavy Gram negative colonization of the oral cavity rela-
tive to non-smokers. Interestingly, women who smoke are
at higher risk of contracting bacterial vaginosis, as dis-
cussed above. Pavlova and Tao showed that the trace
amounts of benzo [a]pyrene diol epoxide that are present
in the vaginal secretions of women who smoke promotes
the induction of bacteriophages in resident lactobacilli
[101]. This may lead to a reduction in lactobacilli popula-
tions and facilitate overgrowth of anaerobes that are asso-
ciated with vaginosis. In general, however, mechanistic
studies to examine the direct influence of tobacco smoke
on bacterial physiology and their pathogenic potential are
lacking in the literature.
Dysregulation of innate immune function
Several innate cell receptor-tobacco agonist couples have
been identified, suggesting that tobacco smoke is capable
of effecting neutrophil and monocyte function both
directly and indirectly [54,102]. Indeed, multiple effector
functions of professional phagocytic and antigen present-
ing innate cells (neutrophils, monocytes, macrophages
and dendritic cells) are compromised by tobacco smoke.
For example, in neutrophils, tobacco smoke and/or nico-
tine have been shown to reduce key anti-microbial activi-
ties including phagocytosis (the engulfment and uptake of
bacteria) [54,103,104]; the generation of a respiratory
burst (the combined oxygen-dependent processes by
which neutrophils kill phagocytosed bacterial cells)
[102,105-107]; and, ultimately, the ability to kill specificTobacco Induced Diseases 2008, 4:12 http://www.tobaccoinduceddiseases.com/content/4/1/12
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bacterial species [102,106]. Compared to unexposed
monocytic cells, tobacco-exposure suppresses general
responsiveness to bacteria and lipopolysaccharide (LPS)
[108], reflected in a down-regulation of surface pathogen
recognition receptors (TLR-2 and MARCO) [109,110];
with reduced phagocytic, reactive-oxygen species generat-
ing, and bacterial killing capacities also reported
[105,106,111]. Dendritic cells, whose primary function is
to process antigen and present them to adaptive immune
cells thus bridging innate and adapative immune
responses, are also negatively influenced by tobacco
smoke and smoke constituents. For example, nicotine
exposure suppresses the maturation dendritic cells that,
subsequently, exhibit a reduced expression of antigen pre-
senting and costimulatory molecules (MHC Class II,
CD80 and CD86), reduced capacity for antigen uptake
and reduced production of T cell stimulating cytokines in
response to the archetypal Gram-negative pro-inflamma-
tory stimulus, LPS [112,113].
Dysregulation of adaptive immune function
The potential effects of smoking on lymphocyte function
are not well understood. However, while IgE levels are
increased in smokers compared to non-smokers, concen-
trations of anti-bacterial IgG levels are reduced [114-118].
This may represent a key underlying mechanism of
Table 1: Bacterial infections associated with tobacco smoking.
Infection OR (95% CI)*
Nasopharyngeal and respiratory pathogens (such as S. pneumonia, N. meningitidis, H. influenzae, L. 
pneumophila)
2.5 (1.1–6.0) [4]
Group A streptococcus sore throat -
Legionnaires disease 3.6 (2.1–5.8) [5]
Cystic fibrosis Increased severity on smoke exposure [134,138]
Pneumonia 2.6 (1.9–3.5)[22,137]
Tuberculosis 1.8 Light [29]
3.2 Moderate [29]
3.7 Heavy [29]
4.1 (2.4 to 7.3) Active [2]
2.5 (1.2 to 5.1) Secondhand [2]
Meningococcal carriage 2.2 (1.0–4.8) Light [38]
7.2 (2.3–22.9 Heavy [38]
Bacterial vaginosis 2.7 [44]
Periductal mastitis 6.2 (2.9–13.4) [131]
Helicobacter pylori 1.9 (1.4–2.5) [51]
Periodontitis 3.3 (2.3–4.5) Light [132]
7.3 (5.1–10.3) Heavy [132]
Ulcerative colitis 0.6 (0.4–0.8) [70]
Crohn's disease 3.6 (2.5 – 5.0) Active [130]
2.0 (1.3 – 3.3) Secondhand [135]
Otitis media 4.2 (1.5–11.9) Secondhand [133]
Surgical infections 1.2 (1.1, 1.3) [136]
* The specific OR (95% CI) presented is selected from a single reference/study. Additional references are provided in the text for more complete 
information.Tobacco Induced Diseases 2008, 4:12 http://www.tobaccoinduceddiseases.com/content/4/1/12
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increased susceptibility to bacterial infection in smokers.
Furthermore, in order to mount a successful humoral
immune response, B cells require T helper cell-derived
cytokines to proliferate and differentiate into plasma cells
and to promote immunoglobulin class switching. How-
ever, it has been shown by several groups that tobacco
smoke reduces T cell proliferative responses to mitogen/
antigen [119-121], with similar tobacco-induced reduc-
tions in B cell proliferative responses also reported [122].
For further details of the influence of tobacco smoke on
the immune system, we point the reader to several exten-
sive reviews [54,69,71,123-129].
Summary
The available evidence supporting tobacco smoke as a risk
factor for multiple and varied bacterial infections is con-
vincing. A summary of bacterial infections associated with
tobacco smoking [2,4,5,22,28,38,44,51,130-138] is pre-
sented in Table 1. Additional references are provided for
more complete information (nasopharyngeal and respira-
tory pathogens [1-3,5,6,9,13,14]; Group A streptococcus
[15]; Legionnaires disease [5,23]; cystic fibrosis [17,18];
pneumonia [2,20,21]; tuberculosis [30-33]; meningococ-
cal carriage [4,34-37,39,139]; bacterial vaginosis
[43,45,46]; periductal mastitis [140,141]; Helicobacter
pylori  [49,50,52,53]; periodontitis [54,123,142-151];
ulcerative colitis [71,152,153]; Crohn's disease
[152,154,155]; otitis media [1,73,156]; and surgical infec-
tions [75,76,80]).
Nevertheless, there are several limitations to many indi-
vidual studies. For example, some studies have small sub-
ject numbers. Others have found associations between
tobacco smoke exposure and infection during in studies
designed to answer different specific questions. Impor-
tantly, many additional factors are independently associ-
ated with bacterial infection, including age,
socioeconomic status, healthcare provision, alcohol, low
physical activity, certain sexual behaviors, and not all
studies reporting on the associations between smoking
and infection have addressed all confounders.
It is also important to note that in the existing literature
on mechanisms of tobacco-induced disease, there is an
overbearing focus on nicotine. While this approach is
valid, it must be remembered that tobacco smoke con-
tains more than 4000 chemicals and there is an urgent
need for studies that examine other components of ciga-
rette smoke as well as whole mainstream and side stream
smoke preparations. To this end, there remains a pressing
need for consensus on the standardization of in vivo and
in vitro modeling systems to permit the generation of a
more robust and reproducible evidence base.
We hope that this review will serve to generate a wider
understanding of the increased susceptibility to infectious
diseases in smoke-exposed individuals; provide further
impetus to efforts aimed at reducing smoke exposure; and
act as a stimulus for further epidemiological and, particu-
larly, mechanistic research into this important area.
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